NCT00987740已完成不适用
A Prospective, Non-Randomized Feasibility Study of the Hemolung Respiratory Assist System in COPD Patients With Acute Respiratory Failure That Are at a 50% Risk of Failing Non Invasive Ventilation (NIV)
Alung Technologies1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2009年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Frequency of occurrence of serious adverse events while on Hemolung therapy and up to 30 days after cessation of therapy and decannulation.
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of the Hemolung Respiratory Assist System in patients with hypercapnic respiratory failure associated with acute exacerbation of chronic obstructive pulmonary disease (COPD) and a 50% likelihood of failure of noninvasive positive pressure ventilation leading to intubation and mechanical ventilation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Moderate or severe COPD, as defined by the GOLD criteria
- •Acute exacerbation of COPD (sustained worsening of patient's condition necessitating a change in regular medication)
- •On non-invasive positive pressure mechanical ventilation > 1hour with either:
- •PaCO2 > 55 mmHg with pH < 7.25 OR
- •PaCO2 > 55 mmHg with < 5mmHg decrease from baseline and pH < 7.30
- •Not severely hypoxemic (PaO2/FiO2 ≥ 200 mmHg on PEEP/CPAP ≤ 5 cmH2O)
- •Hemodynamically stable (mean arterial pressure > 65 mmHg without vasopressor support)
- •Chronic arrhythmias (e.g., atrial fibrillation) well controlled
- •Minimum platelet count of 100,000/mm3
- •Minimum red blood cell count of 2.5 mill/μl
排除标准
- •Presence of acute, uncontrolled arrhythmia
- •Acute ischemic heart disease
- •Presence of bleeding diathesis
- •Significant abnormality or weakness/paralysis of respiratory muscles due to a know muscular dystrophy or neurologic disorder
- •Recent (< 7 days) prolonged (>24 hrs) use of muscle paralyzing agents
- •Cerebrovascular accident, intracranial bleed, head injury or other neurologic disorder likely to affect ventilation
- •Coma from any cause, or decreased consciousness
- •Hypersensitivity to heparin or previous heparin induced thrombocytopenia
- •Recent (< 6 months) major chest abdominal trauma or surgery
- •Presence of septic shock
- •Presence of a significant pneumothorax or bronchopleural fistula
- •History of uncontrolled major psychiatric disorder
- •Pregnant women
- •Known to have AIDS or to have symptomatic HIV
- •Received chemotherapy or radiation within the previous 90 days
- •Received an organ transplant other than corneal transplants
- •Received or currently receiving immunosuppressive therapy, excluding corticosteroids within the last 3 months
- •Presence of severe renal or liver failures
- •Known vascular abnormality with could complicate or prevent successful insertion of the vascular access catheter in the right femoral vein
- •Presence of another catheter in the right femoral vein that cannot be moved
- •Presence of an inferior vena cava filter
研究组 & 干预措施
Hemolung Respiratory Assist System
Experimental
干预措施: Hemolung Respiratory Assist System (Device)
结局指标
主要结局
Frequency of occurrence of serious adverse events while on Hemolung therapy and up to 30 days after cessation of therapy and decannulation.
时间窗: 30 days
Percentage of patients requiring Mechanical Ventilation
时间窗: 7 days
次要结局
- Number of days in the ICU(30 days)
- Number of days in the hospital(30 days)
- Number of days alive and off mechanical ventilation for > 48 hours through the end of Day 30 following completion of Hemolung therapy(30 days)
- Improvement in patient self assessment of dyspnea using visual analog scale pre- to post-Hemolung therapy.(7 days)
- Change in Minute Volume (VE) pre- to end-Hemolung therapy(7 days)
- Percentage of patients requiring sedation, and hours of sedation(30 days)
- Number of days on Non-Invasive Positive Pressure Ventilation (NIPPV)(30 days)
- For patients requiring Mechanical Ventilation, number of days on Mechanical Ventilation(30 days)
- Duration of weaning time from NIPPV(7 days)
- Duration of weaning time from Hemolung therapy(7 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Feasibility Study of the Hemolung Respiratory Assist System (Germany)Hypercapnic Respiratory Failure, COPD, ARDSNCT01021605Alung Technologies21
Unknown
不适用
NIV-FOB, HFNC-FOB- Comparison of MethodsHypoxemic Respiratory FailureHypoxemiaRespiratory FailureNCT05655026Medical University of Silesia300
已完成
不适用
Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Hypercapnic ARFHypercapniaRespiratory InsufficiencyNCT01784367Universitätsklinikum Hamburg-Eppendorf50
终止
2 期
Trimodal Lung-Sparing Treatment of Pleural MesotheliomaPleural MesotheliomaNCT00859495Columbia University9
终止
不适用
Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPDAcute Exacerbation of COPDNCT03255057Alung Technologies113